Impact of Oncotype DX Breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: real world experience in Greater Manchester, UK.
Name:
PIIS0748798317300379.pdf
Size:
346.4Kb
Format:
PDF
Description:
Full text, Open Access Article
Authors
Loncaster, Juliette AArmstrong, Anne C
Howell, Sacha J
Wilson, Gregory
Welch, Richard
Chittalia, Abbas
Valentine, W
Bundred, N
Affiliation
The Christie Hospital, Department of Medical Oncology, 550 Wilmslow Rd, Manchester, M20 4BXIssue Date
2017-01-09
Metadata
Show full item recordAbstract
The National Institute for Health and Clinical Excellence (NICE) recommended the Oncotype DX(®) Breast Recurrence Score(®) (RS) assay as an option for informing adjuvant chemotherapy decisions in node-negative, oestrogen receptor (ER)+, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer assessed to be at intermediate risk of recurrence based on clinicopathological factors. We evaluated the impact of RS testing on adjuvant chemotherapy decision-making in routine clinical practice in a UK Cancer Network.Citation
Impact of Oncotype DX Breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: real world experience in Greater Manchester, UK. 2017, Eur J Surg OncolJournal
European Journal of Surgical OncologyDOI
10.1016/j.ejso.2016.12.010PubMed ID
28111076Type
ArticleLanguage
enISSN
1532-2157ae974a485f413a2113503eed53cd6c53
10.1016/j.ejso.2016.12.010
Scopus Count
Collections
Related articles
- The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience.
- Authors: Crolley VE, Marashi H, Rawther S, Sirohi B, Parton M, Graham J, Vinayan A, Sutherland S, Rigg A, Wadhawan A, Harper-Wynne C, Spurrell E, Bond H, Raja F, King J
- Issue date: 2020 Apr
- [Economic assessment of the routine use of Oncotype DX® assay for early breast cancer in Franche-Comte region].
- Authors: Nerich V, Curtit E, Bazan F, Montcuquet P, Villanueva C, Chaigneau L, Cals L, Méneveau N, Dobi E, Altmotlak H, Algros MP, Choulot MJ, Nallet G, Limat S, Mansion S, Pivot X
- Issue date: 2014 Jul-Aug
- Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
- Authors: Lee SH, Ha S, An HJ, Lee JS, Han W, Im SA, Ryu HS, Kim WH, Chang JM, Cho N, Moon WK, Cheon GJ
- Issue date: 2016 Aug
- Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
- Authors: Partin JF, Mamounas EP
- Issue date: 2011 Nov
- Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
- Authors: Fayaz S, Eissa HE, Demian GA
- Issue date: 2020 Mar 4